During the month of October, the International Cartilage Regeneration & Joint Preservation Society (ICRS) hosted its first virtual convention, allowing stakeholders to come together to learn about the latest cartilage repair techniques, review recent clinical outcomes and explore new products via a virtual hall.

The Regenerative Medicine market for orthopedic and sports medicine applications is rapidly advancing as clinicians increasingly look to novel injectable options to accelerate the healing of injured joints, tendons and/or other soft tissues. Several companies are conducting research into the use of PRP, BMA/BMC, amniotic tissue products, exosomes and other regenerative medicine therapies to treat degenerative and/or chronic conditions such as osteoarthritis (OA), degenerative disc/spine disease, chronic low back pain, tendinopathy and rotator cuff tears. This includes Arthrex, Emcyte, ISTO Biologics, MiMedx and Harvest/Terumo among others.

The following is a sampling of SmartTRAK market updates covering recently published studies, articles and clinical trials in orthopedic regenerative medicine that were compiled, reviewed and posted in real time by Freddy Buntoum, SmartTRAK’s Sr. Analyst, Regenerative Medicine and Sports Medicine.

Heavy-weight contender ​COVID-19 landed some brutal blows to revenue in Q220, but companies look for better days in the second half of 2020. 

The impact of the COVID-19 crisis started to hit the US Joint Fluid Replacement market late in Q120, and, to some degree, this helped to shield HA companies from heavy punches to revenue. Although none were left KO’d in round one, they still came through bruised up. Going into Q220 for round two, HA companies prepared as best as they could and braced for impact. Unfortunately, COVID-19 is a formidable opponent and even with strong cost-control measures in place, companies were hit hard with huge revenue losses for products in the three largest segments of the US Joint Fluid Replacement market.

Among the many topics covered in the comprehensive Q220 US Joint Fluid Replacement Market Recap* are:

 

Companies came out of the gate strong in Q120, but COVID-19’s one-two punch on elective procedures and capital equipment purchases negatively impacted orthopedic enabling technology revenues toward the end of the quarter.

While adoption of robotics and other enabling technologies was gaining significant momentum quarter over quarter through year-end 2019, delays in elective spine surgery due to the COVID-19 pandemic resulted in declines in capital equipment sales and fewer computer-assisted orthopedic surgeries in Q120.

Among the many topics covered in the comprehensive Q120 CAS Ortho Market Recap* are:

The orthobiologics market continues to ramp up studies and new product development as surgeries impacted by COVID-19 are rescheduled. The following is a small sampling of the OrthoBio updates compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor  the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, financial data and competitor developments in the global Life Sciences industry.

A well-oiled engine, the Soft Tissue Fixation train was prepped for a good start to 2020, then COVID-19 sent it in reverse back down the revenue tracks.

Looking back at how 2019 finished, market sentiment was quite optimistic that 2020 could be another positive year for the WW Soft Tissue Fixation Market. With +3.7% YoY growth in Q419, the first quarter of 2020 seemed set for a good start, with companies chugging along nicely, actively pushing products, planning or recruiting for clinical trials, and some of them also receiving FDA 510(k) clearance for new products or for line extensions. All appeared to be business as usual, that is, until COVID-19 reared its ugly head, picking China as its first target. Alas, the rapid worldwide spread of this devastating virus forced a major halt in elective procedures to enable healthcare systems to focus on the rising number of COVID-19 cases. 

Among the many topics covered in the comprehensive Q120 Soft Tissue Fixation Market Recap* are:

The mid-March madness of COVID-19 results in final missed shots for many companies.

For sports fans, March is about celebrating the best in college basketball. Regrettably, March Madness was swapped with COVID-19 mid-March madness, disrupting lives and companies across the world. Since the COVID-19 outbreak, the first corporate earnings season has concluded and we now have a peek of the negative impacts caused by the pandemic and deferral of elective procedures. As for Q120, US orthobiologics revenue declined -5.5% YoY compared to Q119. 

Among the many topics covered in the comprehensive Q120 OrthoBio Market Recap* are:

Coming through Q120 bruised and expecting much harder punches before the calm, companies ride the COVID-19 storm

According to SmartTRAK Financial Dashboard, Q120 revenue for the US Joint Fluid Replacement market was down -2.8%, which is within the range predicted by market leaders and physicians in SmartTRAK’s Impact of COVID-19 on the US Joint Fluid Replacement and Regenerative Medicine Injectable Markets for Knee OA*. Albeit revenue is down for Q120, the stay-at-home orders across US states triggered by the rapid spread of COVID-19 were not implemented until mid-March, which helped to mitigate what could have been much bigger losses. 

Among the many topics covered in the comprehensive Q120 US Joint Fluid Replacement Market Recap* are:

As access to healthcare continues to open up, the orthopedic industry is taking significant precautions to insure the health, safety and piece of mind of patients and caregivers and balance that with its attempt to ramp up services and procedures. The following is a small sampling of the orthopedic updates compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:

Updated Survey Data Points to Recovery by Q420

SmartTRAK discusses the latest advancements in biomedical solutions with DSM President John Witkowski

DSM, a global leader in biomedical solutions for more than 30 years, helps improve the health of 3.5 million patients annually. While biomaterials have been around for decades, DSM Biomedical is advancing biomaterial science, providing the latest synthetic biomaterials and stem cell-based technologies that are used in various applications, including spine, general orthopedics, sports medicine, general surgery and wound.

To learn more about the latest advancements in DSM Biomedical biomaterials and technologies and what’s next for the business, click on the following video to listen to SmartTRAK’s interview with John Witkowski, President of DSM Biomedical. A transcript of the interview can also be downloaded below.